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The treatment of the peptic ulcer disease involves several options. The present
discussion deals with the long-term management with emphasis on the applica-
tion of vagotomy. Eradication ofHelicobacterpylori is the treatment ofchoice
in ordinary peptic ulcer patients. Exceptions are non-steroidal, anti-inflamma-
tory drug-induced ulcers and the Zollinger-Ellison syndrome.
Failures to eradicate H. pylori in old or unfit duodenal ulcer patients and most
gastric ulcer patients will lead to intermittent antisecretory treatment or contin-
uous maintenance treatment. Maintenance treatment will usually mean lifelong
treatment, and optimal results are probably obtained with a full-dose antisecre-
tory regime.
Failures to eradicate H. pylori in young and fit duodenal ulcer patients is the
group ofpatients to whom proximal gastric vagotomy can still be recommend-
ed as an elective surgical procedure. The proximal gastric vagotomy should
preferably be performed with the laparoscopic technique. Evidence is present-
ed that completeness of vagotomy is of clinical importance. The completeness
of vagotomy can be tested and defined.
INTRODUCTION
The therapeutic strategy for peptic ulcer patients has changed dramatically in the last
few years. Previously, most patients were treated with intermittent courses ofantisecreto-
ry drugs, due to the chronically recurrent pattern ofthe ulcer disease. Antisecretory treat-
ment with histamine H2-antagonists resulted in high healing rates and a relatively fast
symptom relief. These results were furtherimproved with the introduction ofomeprazole,
the first proton pump inhibitor. Patients with frequent recurrences or repeated complica-
tions were recommended one out of two prophylactic regimens. Surgery was recom-
mended to young and otherwise fit patients, while maintenance antisecretory treatment
was recommended to older and unfit patients, as well as to those who refused surgery.
Elective gastric resection or vagotomy in combination with a drainage procedure has,
however, mostly been abandoned because ofunpredictable postgastrectomy syndromes in
10-15 percent ofcases. Electiveproximal gastric vagotomy is still a conceivable option in
duodenal ulcerpatients because this procedure does notresultin any postgastrectomy syn-
drome, but it does result in a relatively high recurrence rate if used in patients with gas-
tric ulcers.
The therapeutic strategy has, however, been completely changed with a discovery
that eradication ofHelicobacterpylori will cure the peptic ulcer disease in most patients.
Eradication ofH. pylon is, therefore, the primary therapeutic choice today. The following
discussion will deal with available alternatives for long-term management of the peptic
ulcer disease with emphasis on the application of vagotomy.
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ERADICATION OFH. PYLORI
In peptic ulcer patients, eradication ofH. pyloriis a first-hand choice in mostpatients
[1]. Exceptions are patients with Zollinger-Ellison syndrome and probably patients on
non-steroidal anti-inflammatory drug medication. Apart from these exceptional patients,
practically all patients with recurrent peptic ulcer disease have H. pylori infection, and
they are candidates for H. pylori eradication. However, a patient with a first-time peptic
ulceration should be tested for the presence ofH. pyloriinfection before considering erad-
ication therapy.
There are, however, some problems with the eradication therapy. At present, there are
two alternatives: the triple therapy (bismuth and two antibiotics) or omeprazole twice
daily with one antibiotic (usually amoxycillin). Both therapies are successful injust above
80 percent of patients, but the triple therapy results in more side-effects and, therefore,
less compliance. How do we handle the remaining 20 percent? It seems reasonable to add
at least another eradication trial with a different antibiotic combination to the twice-daily
dose, antisecretory proton pump inhibitor, where most experience involves omeprazole.
Whatever the outcome, there will be a number ofpatients in whom even a repeated erad-
ication trial will fail. Furthermore, some peptic ulcer patients will be re-infected with H.
pylori after a successful eradication. The re-infection rate is claimed to be surprisingly
low, but the long-term results are unknown. Those peptic ulcer patients still having the H.
pylori infection should be managed by a different strategy.
ANTISECRETORY TREATMENT
Intermittent treatment
Most peptic ulcer patients who have had unsuccessful eradication treatment have
rather infrequent symptomatic episodes (i.e., fewer than one to two episodes each year).
These patients can be easily managed by intermittent treatment over four to six weeks.
Antisecretory drugs are most efficient. Proton pump inhibitors are superior to histamine
H2-receptor antagonists, both with regard to healing rates and fast symptom relief.
Continuous maintenance treatment
Some peptic ulcer patients who have had unsuccessful eradication ofH. pylori have
a more severe disease with more or less continuous symptoms or repeated complications
and may not be suitable for surgery or willing to accept surgery. Atypical example is the
older patient who has had repeated peptic ulcer bleedings and has other severe, concomi-
tant disease. Such patients should be given continuous maintenance treatment.
There is vast experience with continuous maintenance treatment with histamine H2-
receptor antagonists such as cimetidine, ranitidine, famotidine and nizatidine.
Traditionally, the maintenance dose has been halfthe dose used forhealing a peptic ulcer.
The recurrence rate during half-dose maintenance treatment with any ofthe histamine H2-
receptor antagonists has been up to 25-30 percent for the first 12 months. This recurrence
rate is much lower than that obtained during placebo treatment but certainly is not satis-
factory. The same rather poor results have been obtained during half-dose maintenance
treatment with omeprazole [2, 3]. Consequently, there seems to be a case for more potent
medical prophylaxis in the maintenance therapy for peptic ulcer (e.g., a full-dose antise-
cretory regimen).
There are no reports of full-dose maintenance treatment with histamine H2-receptor
antagonists. There are, however, some reports of full-dose maintenance treatment with
omeprazole [4, 5]. In these studies, the recurrence rate during the first 12 months has
reached amoresatisfactory level ofabout 10 percent. This recurrence rate seems to remain
stable over a prolonged period of full-dose maintenance treatment with omeprazole [4]
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and is thus comparable with the recurrence rate after proximal gastric vagotomy for duo-
denal ulcer.
INDICATIONS FOR SURGERY
The indications for elective surgery for peptic ulcer disease have been completely
changed. Previously, the main indication was "failure of medical therapy." This is obvi-
ously no longer valid. Almost all peptic ulcers can now be healed by medical therapy, but
it is a question ofchoice ofdrug and dosage. At present, elective surgery is an alternative
to continuous life-long, full-dose maintenance, antisecretory, therapy for relatively young
and otherwise fit patients. Aprerequisite is that the surgical procedures should have good
long-term results and exceptionally low mortality and morbidity. Proximal gastric vago-
tomy for duodenal ulcer seems to be an acceptable procedure, although it results in too
high a recurrence rate of 30-35 percent when performed for pyloric or prepyloric ulcers
[6, 7]. The surgical procedures for gastric ulcers involve a gastric resection or vagotomy
with a drainage operation. Since these procedures will result in severe and unpredictable
postgastrectomy syndromes in 10-15 percent ofthe patients, the indication for this type of
elective operations should be very restrictive.
Closure of a duodenal ulcer perforation can usually be performed by laparoscopic
surgery. Additional proximal gastric vagotomy might be considered in a young patient
with a short perforation history and severe recurrent ulcer disease [8]. Bleeding from a
peptic ulcer can be stopped in 90-95 percent ofpatients by endoscopic techniques. When
open surgery is required for a bleeding ulcer, vagotomy might be considered in addition
to stitching the bleeding vessel in a young patient with severe recurrent ulcer disease. The
stitching can sometimes be performed via an incision in only the duodenal bulb of a
patient with a duodenal ulcer, but often a pylorotomy is needed.
Elective proximal gastric vagotomy
The number of proximal gastric vagotomies performed in recent years has been
reduced to a very low figure. With the indications stated above, there will be a place for a
few proximal gastric vagotomies, particularly since they now can be performed as a
laparoscopic procedure. It is, however, absolutely essential that the vagotomy should
result in a minimal number of incomplete vagotomies. The technique used for laparo-
scopic vagotomy should not be allowed tojeopardize the completeness of vagotomy just
because it is a laparoscopic procedure. Therefore, it seems reasonable that the laparo-
scopic proximal gastric vagotomy should be performed in exactly the same way as during
open surgery. Ifmodifications in the surgical technique are introduced, they must be eval-
uated with regard to the frequency ofincomplete vagotomies obtained.
Testfor completeness ofvagotomy
Traditionally, the insulin test has been used. This test, however, entails some risk.
Furthermore, it results in a number offalse-negative results because ofextravagal inhibi-
tion of gastric acid secretion and false-positive results because of extra-vagal release of
gastrin [9]. Afterproximal gastric vagotomy, 80patients were tested both with sham-feed-
ing and an intravenous dose of 0.2 IU insulin/kg body weight. Divergent results were
obtained in 30 patients. A positive sham-feeding test and a negative insulin test were
obtained in 12 patients, and four ofthese accepted further testing. The four patients had a
mean acid increase of 2.34 mmol/30 min on sham-feeding, while 0.2 IU insulin/kg body
weight only increased the acid output by 0.07 mmol/30 min. Repeating the insulin test
with a reduced dose of insulin to 0.1IU/kg resulted in a marked increase of acid output
by 1.11 mmol/30 min. Thus, the ordinary dose ofinsulin had obviously produced a false
negative result.
155Olbe: Vagotomy in 1993
Five patients with a negative sham-feeding response (0-0.5 mmol/30 min) and a pos-
itive response to insulin at a dose of 0.2 IU/kg (1.31 mmol/30 min) accepted further test-
ing. The insulin test was repeated with the same dose of insulin, but in addition, the beta-
adrenergic antagonist propranolol was injected at a dose of 0.1 mg/kg. This time the
insulin test resulted in an increase of acid output of only 0.1 mmol/30 min. The reason for
the design of the experiment was that insulin hypoglycemia is known to induce liberation
ofepinephrine from the adrenals, and intravenous infusion ofepinephrine has been shown
to release gastrin in man [10]. This extra-vagal release of gastrin should be blocked by a
beta-adrenergic antagonist. In any case, the insulin test produced a false-positive result in
these five patients. Therefore the simple, reproducible and safe sham-feeding test seems
to be a more reliable postoperative test for completeness of vagotomy than the insulin test
The criterionfor incompleteness ofvagotomy
Different criteria for incompleteness of vagotomy have been published previously.
They all lack the necessary information about the spontaneous oscillations of the basal
acid secretion in subjects with an unequivocal vagotomy. Therefore, we studied 10
patients who had been subjected to resection of the esophagus and reconstructed with an
esophago-gastric anastomosis. The operation certainly resulted in transsection ofall vagal
innervation to the stomach. The oscillations of basal acid secretion were studied over a
three-hr period. The difference (plus two standard deviations) between the highest and
lowest recorded 15-min output was 0.6 mmol [11]. Subsequent sham-feeding produced no
further increase of the acid output. Furthermore, the oscillations in basal acid secretion
were also studied in 20 duodenal ulcer patients after proximal gastric vagotomy. Early
postoperative tests had shown them to be presumably completely vagotomized and they
had been asymptomatic for seven to 10 years. The difference (plus two standard devia-
tions) between the highest and lowest recorded 15-min output was again 0.6 mmol.
Consequently, a reasonable criterion for incompleteness of vagotomy is an acid response
to sham-feeding which exceeds the lowest basal secretion by more than 0.6 mmol/15 min.
Is completeness ofvagotomy ofclinical importance?
The recurrence rate after proximal gastric vagotomy is highly variable with a range
of 10-40 percent. The impact of complete vagotomy on recurrence rate is uncertain. The
role of completeness of vagal denervation in determining the long-term outcome after
proximal gastric vagotomy for duodenal ulcer disease was studied by relating the early
postoperative acid response to sham-feeding to the subsequent ulcer relapse rate observed
during a mean follow-up period of 7.5 years (five to 15 years) in 98 patients [12]. The
relapse rate for the whole group was11 percent. Within five years after the operation, 23
percent of those with an incomplete vagotomy had an ulcer relapse, while only three per-
cent of those with a complete vagotomy had a relapse. This difference is significant.
However, four patients with a complete vagotomy had an ulcer relapse more than five
years after the operation. Obviously, a complete vagotomy implies a low risk for ulcer
relapse.
IS THERE A PLACE FOR THE CLASSICAL DRAGSTEDT OPERATION?
Some patients present with a long fibrous stenosis ofthe postpyloric region after innu-
merable courses ofshort-term medical treatment for duodenal ulcer. In this particular case,
a truncal vagotomy with a gastroenterostomy, Dragstedt's classical operation [13], seems
most appropriate. Asimilar operation, truncal vagotomy with pyloroplasty and stitching of
a bleeding ulcer, is often the simplest solution to treat a bleeding juxtapyloric ulcer that
could not be handled by endoscopic techniques. Proximal gastric vagotomy is, however,
the most frequent vagotomy procedure for duodenal ulcer, and selective vagotomy with
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antrectomy or pyloroplasty is probably the most frequent surgical procedure for pyloric-
prepyloric ulcers.
CONCLUSION
Eradication of H. pylori is the therapeutic strategy ofchoice in ordinary peptic ulcer
patients. Exceptions are non-steroidal, anti-inflammatory, drug-induced peptic ulcers and
the Zollinger-Ellison syndrome. In patients with frequent recurrences or repeated compli-
cations, and in whom repeated attempts to eradicate H. pylori have failed, proximal gas-
tric vagotomy is a prophylactic procedure to consider in young and fit duodenal ulcer
patients, particularly ifit can be performed as a laparoscopic procedure. Such aprocedure
should be performed in a surgical department with a high success rate in performing com-
plete vagotomies.
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